AUROBINDO PHARMA RECEIVES USFDA APPROVAL FOR PAZOPANIB TABLET
News: Eugia Pharma Specialities, a wholly owned subsidiary of Aurobindo Pharma, has received a final approval from the USFDA to manufacture and market Pazopanib Tablets, 200 mg. It is therapeutically equivalent to Votrient Tablets, 200 mg of Novartis Pharmaceuticals. It is indicated for the treatment of Renal Cell Cancer. Pazopanib has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA.
Views: This is a niche oral kidney cancer drug. However, there are already four generic players with approval besides Aurobindo. Out of them, Sun and Teva have already launched the product in 2023. Hence the traction from this drug could be limited.
ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Centre, H. T. Parekh Marg, Churchgate, Mumbai - 400020, India, Tel No : 022 - 2288 2460, 022 - 2288 2470.I-Sec is a SEBI registered with SEBI as a Research Analyst vide registration no. INH000000990.. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The information mentioned herein above is only for consumption by the client and such material should not be redistributed.
The information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities Limited. The contents of this mail are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. While due care has been taken in preparing this mail, I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any inaccurate, delayed or incomplete information nor for any actions taken in reliance thereon. This mail is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject I-Sec and affiliates to any registration or licensing requirement within such jurisdiction